A document outlining the proposed project scope for CADTH’s project on anti–vascular endothelial growth factor drugs for retinal conditions is now available for feedback from all interested stakeholders.

CADTH is undertaking a therapeutic review comparing the clinical and economic effectiveness of anti-VEGF drugs (aflibercept, bevacizumab, pegaptanib, ranibizumab) for the treatment of the following retinal conditions: AMD, choroidal neovascularization (CNV), diabetic macular edema (DME), pathologic myopia (PM), and retinal vein occlusion (RVO). The therapeutic review project will include a science report (clinical and economic evaluations) and a recommendations report.

For more details, go to: https://www.cadth.ca/anti-vascular-endothelial-growth-factor-drugs-retinal-conditions